Presenting new therapeutic solutions to a global audience

Our platform has too much potential to keep it secret. Which is why we publish, inform, and present. After all, you want to know where your future therapies are starting.

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

Press releases

Greenovation transforms into Eleva

May 18, 2020

Greenovation is launching its supreme moss-based development platform with a new business model and is transforming into a new company, Eleva.

READ MORE

Eleva’s drug candidate to be examined for use in Covid-19 treatment

June 3, 2020

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

READ MORE

Meet us here

Dec 07 2020 - Dec 08 2020

BioFIT

Straßbourg, France
No event found!
Load More

In the press

Press kit

For non-commercial purposes only. Please only use the material in combination with Eleva GmbH copyright label.

Boilerplate

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.

eleva Newsletter